CGEM

SEC source: 0000899243-21-002076 · doc4.xml · nonDerivative · entry 2

GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,136,525

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-002081 · doc4.xml · derivative · entry 9

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner

MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 649,030 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F3 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

SEC source: 0000899243-21-002081 · doc4.xml · derivative · entry 8

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner

MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,276,692 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F3 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

SEC source: 0000899243-21-002081 · doc4.xml · derivative · entry 7

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner

MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,551,640 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F3 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

SEC source: 0000899243-21-002081 · doc4.xml · derivative · entry 6

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner

MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,136,525 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F3 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

SEC source: 0000899243-21-002081 · doc4.xml · nonDerivative · entry 5

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner

MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,913,887

F4 · kind: On January 12, 2021, OIF purchased 300,000 shares of Common Stock of the Issuer at a price of $21.00 per share pursuant to the Issuer's initial public offering.

F2 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F3 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

SEC source: 0000899243-21-002081 · doc4.xml · nonDerivative · entry 4

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner

MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,613,887

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F3 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

SEC source: 0000899243-21-002081 · doc4.xml · nonDerivative · entry 3

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner

MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,964,857

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F3 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

SEC source: 0000899243-21-002081 · doc4.xml · nonDerivative · entry 2

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner

MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,688,165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F3 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

SEC source: 0000899243-21-002081 · doc4.xml · nonDerivative · entry 1

UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner

Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner

MPM Oncology Impact Management GP LLC · CIK 0001721035 · 10% owner

MPM Oncology Impact Management LP · CIK 0001687078 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,136,525

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F3 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

SEC source: 0000899243-21-002046 · doc4.xml · nonDerivative · entry 1

Hughes Owen · CIK 0001575933 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,226

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 21

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 214,798 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F8 · ownership.nature: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 20

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 71,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F7 · ownership.nature: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 19

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 143,198 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 18

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 71,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 17

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 182,135 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 16

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 455,338 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 15

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 639,295 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F4 · ownership.nature: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 14

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,912,345 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F3 · ownership.nature: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 13

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,136,525 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F2 · ownership.nature: These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 12

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 104,762

F9 · ownership.nature: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 11

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 622,175

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 10

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 214,798

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F8 · ownership.nature: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 9

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 71,599

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F7 · ownership.nature: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 8

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 325,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 7

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 526,937

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 6

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 182,135

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 5

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 455,338

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 4

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 639,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F4 · ownership.nature: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 3

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,912,345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F3 · ownership.nature: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,136,525

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F2 · ownership.nature: These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-002047 · doc4.xml · nonDerivative · entry 1

Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,250

SEC source: 0000899243-21-001365 · doc4.xml · derivative · entry 1

Hughes Owen · CIK 0001575933 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 433,332

Underlying: Common Stock · 433,332 shares

Expires 2031-01-06

F1 · derivative.exercise_date: The option represents a right to purchase a total of 433,332 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer.

SEC source: 0000899243-21-001359 · doc4.xml · derivative · entry 1

Keane Raymond T · CIK 0001448434 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,998

Underlying: Common Stock · 249,998 shares

Expires 2031-01-06

F1 · derivative.exercise_date: The option represents a right to purchase a total of 249,998 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer.

SEC source: 0000899243-21-001369 · doc4.xml · derivative · entry 1

Baeuerle Patrick · CIK 0001362054 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 286,665

Underlying: Common Stock · 286,665 shares

Expires 2031-01-06

F1 · derivative.exercise_date: The option represents a right to purchase a total of 286,665 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer.

SEC source: 0000899243-21-001360 · doc4.xml · derivative · entry 1

Wigginton Jon Marc · CIK 0001587487 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,666

Underlying: Common Stock · 116,666 shares

Expires 2031-01-06

F1 · derivative.exercise_date: The option represents a right to purchase a total of 116,666 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer.

SEC source: 0000899243-21-001367 · doc4.xml · derivative · entry 1

Zawel Leigh · CIK 0001837456 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,666

Underlying: Common Stock · 56,666 shares

Expires 2031-01-06

F1 · derivative.exercise_date: The option represents a right to purchase a total of 56,666 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer.

SEC source: 0000899243-21-001366 · doc4.xml · derivative · entry 1

Michaelson Jennifer · CIK 0001838061 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,999

Underlying: Common Stock · 79,999 shares

Expires 2031-01-06

F1 · derivative.exercise_date: The option represents a right to purchase a total of 79,999 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer.

SEC source: 0000899243-21-001361 · doc4.xml · derivative · entry 1

Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,665

Underlying: Common Stock · 146,665 shares

Expires 2031-01-06

F1 · derivative.exercise_date: The option represents a right to purchase a total of 146,665 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer.

SEC source: 0000899243-21-002076 · doc4.xml · derivative · entry 12

GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,824

Underlying: Common Stock · 88,824 shares

Expires 2030-10-28

F3 · kind: In connection with the Issuer's initial public offering, on January 7, 2021, these securities of the Issuer were received pursuant to a corporate reorganization.

F3 · price: In connection with the Issuer's initial public offering, on January 7, 2021, these securities of the Issuer were received pursuant to a corporate reorganization.

F2 · derivative.exercise_date: 25% of the shares vested on March 8, 2018, and the remaining shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0000899243-21-002076 · doc4.xml · derivative · entry 11

GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,114

Underlying: Common Stock · 262,114 shares

Expires 2030-10-28

F3 · kind: In connection with the Issuer's initial public offering, on January 7, 2021, these securities of the Issuer were received pursuant to a corporate reorganization.

F3 · price: In connection with the Issuer's initial public offering, on January 7, 2021, these securities of the Issuer were received pursuant to a corporate reorganization.

F2 · derivative.exercise_date: 25% of the shares vested on March 8, 2018, and the remaining shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0000899243-21-002076 · doc4.xml · derivative · entry 10

GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 649,030

Underlying: Common Stock · 649,030 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · kind: In connection with the Issuer's initial public offering, on January 7, 2021, these securities of the Issuer were received pursuant to a corporate reorganization.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-002076 · doc4.xml · derivative · entry 9

GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,276,692

Underlying: Common Stock · 2,276,692 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · kind: In connection with the Issuer's initial public offering, on January 7, 2021, these securities of the Issuer were received pursuant to a corporate reorganization.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-002076 · doc4.xml · derivative · entry 8

GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 3,551,640

Underlying: Common Stock · 3,551,640 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · kind: In connection with the Issuer's initial public offering, on January 7, 2021, these securities of the Issuer were received pursuant to a corporate reorganization.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-002076 · doc4.xml · derivative · entry 7

GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,136,525

Underlying: Common Stock · 1,136,525 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · kind: In connection with the Issuer's initial public offering, on January 7, 2021, these securities of the Issuer were received pursuant to a corporate reorganization.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F4 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.

F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-21-002076 · doc4.xml · nonDerivative · entry 1

GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 281,268

F3 · kind: In connection with the Issuer's initial public offering, on January 7, 2021, these securities of the Issuer were received pursuant to a corporate reorganization.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.